Cynata Therapeutics Limited

CYP

AU000000CYP7

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 01:51:49 2024-05-21 am EDT			5-day change	1st Jan Change
0.275 ^AUD	-5.17%		+12.24%	+120.00%

Apr. 08	Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial	CI
Apr. 08	Cynata Therapeutics Concludes Patient Enrolment in Diabetic Foot Ulcer Wound Dressing Product Trial	MT

Howard Digby Steps Down as Non-Executive Director of Cynata Therapeutics

November 17, 2014 at 07:25 pm EST

Cynata Therapeutics Ltd. announced that Mr. Howard Digby has stepped down from his role as a Non-Executive Director, at the conclusion of the annual general meeting.

Latest news about Cynata Therapeutics Limited

Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial	Apr. 07	CI
Cynata Therapeutics Concludes Patient Enrolment in Diabetic Foot Ulcer Wound Dressing Product Trial	Apr. 07	MT
Cynata Therapeutics Receives EU Approval for CYP-001 Phase 2 Trial	Mar. 19	MT
Cynata Therapeutics Doses First Patient in Phase Two Trial of Cellular Therapy; Shares Rise 5%	Mar. 04	MT
Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001	Mar. 04	CI
Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14%	Feb. 28	MT
Cynata Therapeutics Limited Announces Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial	Feb. 26	CI
Cynata Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 22	CI
Cynata Therapeutics Expects Initial Results in Diabetic Foot Ulcer Topical Wound Dressing Trial in Q1 2024	Dec. 27	MT
Cynata Therapeutics Completes Recruitment for Phase Three Osteoarthritis Trial	Dec. 12	MT
Cynata Therapeutics Secures Approval in Turkey for Phase 2 Trial of HR-aGvHD; Shares Jump 9%	Dec. 07	MT
Cynata Therapeutics Receives AU$2.3 Million R&D Tax Rebate	Nov. 13	MT
Cynata Therapeutics Secures Clearance to Advance Phase Three Knee Pain Trial	Nov. 06	MT
Cynata Therapeutics Limited Announces Resignation of David Atkins as Director	23-10-08	CI
Cynata Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-28	CI
Cynata Therapeutics Opens Enrollment for Phase Two Cell Therapy Trial	23-08-10	MT
Cynata Therapeutics Taps COO for CEO/Managing Director Role; Shares Down 4%	23-06-30	MT
Cynata Therapeutics Limited Announces Management Appointments	23-06-29	CI
Cynata Therapeutics Limited Announces Chief Executive Officer Changes	23-06-29	CI
Cynata Therapeutics Completes Oversubscribed Share Purchase Plan	23-05-10	MT
Cynata Therapeutics Secures Ethics Approval for Phase Two Trial	23-04-12	MT
Cynata Therapeutics to Raise AU$5 Million Via Share Placement	23-04-06	MT
Cynata Therapeutics Adds Three New Sites for DFU Clinical Trial	23-03-16	MT
Cynata Therapeutics Limited Adds New Sites for DFU Clinical Trial	23-03-15	CI
Cynata Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI

Chart Cynata Therapeutics Limited

Duration

Period

More charts

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYNATA THERAPEUTICS LIMITED	+120.00%	34.79M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	107B
ARGENX SE	-3.46%	21.6B
BIONTECH SE	-12.38%	22.31B
GENMAB A/S	-6.87%	19.19B
BEIGENE, LTD.	-3.35%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.26B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.37B

Bio Therapeutic Drugs

Cynata Therapeutics Limited

Equities

CYP

AU000000CYP7

Biotechnology & Medical Research

Howard Digby Steps Down as Non-Executive Director of Cynata Therapeutics

Latest news about Cynata Therapeutics Limited

Chart Cynata Therapeutics Limited

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs